文献速递抗栓抗凝管理抗菌药物管理

症状性外周动脉疾病的抗血栓治疗:系统综述与网络荟萃分析

Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis.
PubMed 文献 · Drugs · 2022-08-23

结果显示氯吡格雷、替格瑞洛、ASA联合替格瑞洛及ASA联合低剂量利伐沙班在预防主要不良心血管事件(MACE)方面均优于ASA单药且彼此等效,但仅ASA联合低剂量利伐沙班增加大出血风险;外周血运重建3个月后,ASA联合低剂量利伐沙班在预防MACE和主要不良肢体事件(MALE)方面优于ASA。

要点

  • 氯吡格雷、替格瑞洛、ASA联合替格瑞洛及ASA联合低剂量利伐沙班预防MACE均优于ASA且彼此等效。
  • 四种优于ASA的方案中仅ASA联合低剂量利伐沙班增加大出血风险。
  • 外周血运重建>3个月后ASA联合低剂量利伐沙班在预防MACE和MALE上优于ASA但出血风险更高。

核心结论

  • 氯吡格雷、替格瑞洛、ASA联合替格瑞洛及ASA联合低剂量利伐沙班在预防MACE方面优于ASA单药且彼此等效。
  • 四种方案中仅ASA联合低剂量利伐沙班增加大出血风险。
  • 外周血运重建>3个月后ASA联合低剂量利伐沙班在预防MACE和MALE方面优于ASA但出血风险更高。

研究设计与样本

  • 系统检索随机对照试验并进行频率学网络荟萃分析,以ASA为共同对照。

主要发现

  • 降低MACE方面,氯吡格雷(RR 0.78,95%CI 0.66-0.93)、替格瑞洛(RR 0.79,95%CI 0.65-0.97)、ASA联合替格瑞洛(RR 0.79,95%CI 0.64-0.97)及ASA联合低剂量利伐沙班(RR 0.84,95%CI 0.76-0.93)均优于ASA且彼此等效。
  • 与ASA相比,维生素K拮抗剂、利伐沙班、ASA联合维生素K拮抗剂及ASA联合低剂量利伐沙班的大出血发生更频繁。
  • 所有方案在MALE方面与ASA相似,而ASA联合低剂量利伐沙班在预防急性肢体缺血(ALI)方面更有效(RR 0.67,95%CI 0.55-0.80)。
  • 外周血运重建亚组分析中,≥3个月后氯吡格雷、替格瑞洛及ASA联合替格瑞洛缺乏获益证据,而ASA联合低剂量利伐沙班在预防MACE(RR 0.87,95%CI 0.78-0.97)和MALE(RR 0.89,95%CI 0.81-0.97)方面优于ASA。
  • 外周血运重建≥3个月后ASA联合氯吡格雷在预防MACE方面不优于ASA。

关键数值与推荐

  • 主要终点为MACE和大出血,次要终点为MALE和ALI。
  • 氯吡格雷降低MACE的RR为0.78(95%CI 0.66-0.93),替格瑞洛为0.79(95%CI 0.65-0.97)。
  • ASA联合替格瑞洛降低MACE的RR为0.79(95%CI 0.64-0.97),ASA联合低剂量利伐沙班为0.84(95%CI 0.76-0.93)。
  • ASA联合低剂量利伐沙班预防ALI的RR为0.67(95%CI 0.55-0.80)。
  • 外周血运重建≥3个月后ASA联合低剂量利伐沙班预防MACE的RR为0.87(95%CI 0.78-0.97),预防MALE的RR为0.89(95%CI 0.81-0.97)。

临床怎么用

  • 基于当前证据,氯吡格雷可考虑作为大多数PAD患者的首选抗血栓治疗。
  • 对于接受外周血管介入的患者,可考虑长期(>3个月)使用ASA联合低剂量利伐沙班预防MACE和MALE。
  • 选用ASA联合低剂量利伐沙班时需权衡其较高的出血风险。

局限性

  • 外周介入术后3个月内的抗血栓治疗策略缺乏证据。
  • 外周血运重建亚组分析中,≥3个月后氯吡格雷、替格瑞洛及ASA联合替格瑞洛缺乏获益证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-quality evidence from trials directly comparing single antiplatelet therapies in symptomatic peripheral arterial disease (PAD) to dual antiplatelet therapies or acetylsalicylic acid (ASA) plus low-dose rivaroxaban is lacking. Therefore, we conducted a network meta-analysis on the effectiveness of all antithrombotic regimens studied in PAD. METHODS: A systematic search was conducted to identify randomized controlled trials. The primary endpoints were major adverse cardiovascular events (MACE) and major bleedings. Secondary endpoints were major adverse limb events (MALE) and acute limb ischaemia (ALI). For each outcome, a frequentist network meta-analysis was used to compare relative risks (RRs) between medication and ASA. ASA was the universal comparator since a majority of studies used ASA as in the reference group. RESULTS: Twenty-four randomized controlled trials were identified including 48,759 patients. With regard to reducing MACE, clopidogrel [RR 0.78, 95% confidence interval (CI) 0.66-0.93], ticagrelor (RR 0.79, 95% CI 0.65-0.97), ASA plus ticagrelor (RR 0.79, 95% CI 0.64-0.97), and ASA plus low-dose rivaroxaban (RR 0.84, 95% CI 0.76-0.93) were more effective than ASA, and equally effective to one another. As compared to ASA, major bleedings occurred more frequently with vitamin K antagonists, rivaroxaban, ASA plus vitamin K antagonists, and ASA plus low-dose rivaroxaban. All regimens were similar to ASA concerning MALE, while ASA plus low-dose rivaroxaban was more effective in preventing ALI (RR 0.67, 95% CI 0.55-0.80). Subgroup analysis in patients undergoing peripheral revascularization revealed that ≥ 3 months after intervention, evidence of benefit regarding clopidogrel, ticagrelor, and ASA plus ticagrelor was lacking, while ASA plus low-dose rivaroxaban was more effective in preventing MACE (RR 0.87, 95% CI 0.78-0.97) and MALE (RR 0.89, 95% CI 0.81-0.97) compared to ASA. ASA plus clopidogrel was not superior to ASA in preventing MACE ≥ 3 months after revascularization. Evidence regarding antithrombotic treatment strategies within 3 months after a peripheral intervention was lacking. CONCLUSION: Clopidogrel, ticagrelor, ASA plus ticagrelor, and ASA plus low-dose rivaroxaban are superior to ASA monotherapy and equally effective to one another in preventing MACE in PAD. Of these four therapies, only ASA plus low-dose rivaroxaban provides a higher risk of major bleedings. More than 3 months after peripheral vascular intervention, ASA plus low-dose rivaroxaban is superior in preventing MACE and MALE compared to ASA but again at the cost of a higher risk of bleeding, while other treatment regimens show non-superiority. Based on the current evidence, clopidogrel may be considered the antithrombotic therapy of choice for most PAD patients, while in patients who underwent a peripheral vascular intervention, ASA plus low-dose rivaroxaban could be considered for the long-term (> 3 months) prevention of MACE and MALE.

来源:Drugs,查看原文。版权归原作者所有。

引用

  1. Willems LH, Maas DPMSM, Kramers K, et al. Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis. Drugs. 2022. PMID: 35997941. doi:10.1007/s40265-022-01756-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。